Coverage spread: 2 sources — 2 center
Lean ratings via AllSides / Media Bias-Fact-Check. How this works.
Where they agree
- Novo Nordisk raised its full-year financial guidance after a stronger-than-expected quarter.
- Novo’s shares fell after the results, reflecting investor skepticism despite the guidance increase.
- Eli Lilly’s rival drugs Zepbound and Mounjaro, launched later, have taken significant market share from Novo’s Ozempic and Wegovy.
- Lower prices on Novo’s drugs are weighing on sales even as volumes grow.
Where they differ
- CNBC focuses tightly on the earnings call, CEO Mike Doustdar’s comments, and analyst reactions from Citi and Jefferies.
- MarketWatch frames the story as a broader narrative of Novo losing its first-mover advantage to Eli Lilly and raises a wider question about European competitiveness.
- CNBC includes specific figures (7% sales growth, 11% profit growth, guidance ranges) that MarketWatch’s more strategic framing does not mention.
- MarketWatch emphasizes the historical and competitive angle, while CNBC emphasizes near-term financial mechanics like rebates and pipeline data such as the CagriSema trial results.
What Novo Nordisk reported
Novo Nordisk, the Danish maker of Ozempic and Wegovy, raised its full-year financial guidance after posting better-than-expected quarterly results, but its shares still fell roughly 5-6% on the news. The company reported second-quarter adjusted sales up 7% and adjusted operating profit up 11%, both at constant exchange rates. It now expects full-year adjusted sales and operating profit to range from down 6% to flat, an improvement from its prior guidance of a decline of 4% to 12% on both measures.
CEO Mike Doustdar told CNBC that rising sales volumes and early sales of the oral version of Wegovy showed the company’s strategy of cutting prices to drive demand was working. He said Novo could not be posting growth on both revenue and profit if the pill were not selling well and generating a profit, and described the company’s approach as searching for a “sweet spot” between price and volume, with pricing likely to keep shifting as the market develops. He pointed to double-digit volume growth in the quarter, even as lower prices continued to weigh on the top line.
Why Wall Street wasn’t convinced
Despite the beat, analysts flagged reasons for caution. Citi and Jefferies both described the results as underwhelming: Citi said there was “nothing to inspire,” while Jefferies noted the raised guidance left little room for consensus sales forecasts to climb further. Analysts pointed out that much of the earnings beat came from rebate adjustments and other one-off factors rather than core strength, that obesity-drug sales roughly matched expectations, and that sales of the oral Wegovy pill came in slightly below forecasts. Novo also reported another mixed clinical readout for CagriSema, its next-generation weight-loss drug, adding to doubts about the strength of its future pipeline.
The bigger competitive picture
The financial results land against a backdrop of Novo losing ground in the weight-loss drug market it essentially created. A separate account of the company’s trajectory describes how Novo developed what became the most commercially successful new drug category in the world, only to be overtaken by American rival Eli Lilly. Lilly’s competing drugs, Zepbound and Mounjaro, were launched years after Novo’s Ozempic and Wegovy but have rapidly taken market share in the crucial U.S. market, reversing what had looked like a commanding lead for the Danish firm.
That erosion is the central tension behind Wednesday’s stock reaction: Novo is trying to convince investors it has a credible way back to steady growth even as Lilly’s momentum builds. Cutting prices and pushing volume, along with betting on the convenience of an oral pill instead of injections, are the tools Novo is using to try to hold its ground.
How the coverage differs
CNBC’s account is narrowly focused on the quarterly numbers, the CEO’s defense of the pricing strategy, and the skeptical analyst reaction, treating this as a story about whether Novo can execute its pivot to the pill. MarketWatch’s piece takes a wider lens, framing the story as one of competitive failure — how a Danish company invented the category and then let an American rival, Eli Lilly, seize control of it — and ties that into a broader question about whether European companies can compete in high-stakes global industries. CNBC supplies the granular financial detail (guidance ranges, growth percentages, analyst quotes) that MarketWatch’s framing largely omits, while MarketWatch supplies the strategic backstory and geopolitical angle that CNBC’s earnings-focused report leaves out.
Why it matters
Novo Nordisk was, until recently, one of Europe’s most valuable companies and a rare European success story in a market otherwise dominated by American pharmaceutical firms. Its struggle to defend that position against Eli Lilly is being watched not just as a corporate rivalry but as a test case for whether European drugmakers can hold their own against U.S. competitors in fast-moving, high-value markets. For now, Novo’s answer is to compete on price and bet that a pill will be easier to sell at scale than an injection — a strategy its own CEO is having to actively defend to skeptical investors.
Sources
Featured photo: Bain News Service via Wikimedia Commons (Public domain)